For diabetic workers, access to a refrigerator and insulin breaks are not a workplace perk. They are potentially a matter of life and death.

Read More: https://www.bizjournals.com/sanjose/news/2019/05/22/disease-management-companies-on-the-rise-omada.html

Gary Sunderland was recovering from a heart procedure at New Hanover Regional Medical Center when a physician assistant stopped by to assess him. Using a stethoscope, the physician assistant listened to the carotid artery in his neck.
She didn’t like what she heard.

He got a referral to a vascular surgeon and discovered he had blockages in his carotid arteries, which carry oxygenated blood to the brain. Carotid artery disease, which happens when plaque clogs the blood vessels, increases the risk of a stroke.
“It was like a ticking time bomb,” said Sunderland, who is 81 and has enjoyed good health all his life.

​The most commonly performed surgery to remedy blocked carotid arteries is a carotid endarterectomy, which involves a surgeon opening the artery to remove the plaque. This procedure is offered at NHRMC, but it is invasive and not ideal for everyone.

After reviewing Sunderland’s case, Dr. Michael Patton, a Wilmington vascular surgeon, recommended a minimally invasive procedure to place stents in his carotid arteries, lowering his risk of stroke. Patton placed the stents, which are small mesh tubes, using the TCAR procedure, which stands for transcarotid artery revascularization.

Read More: https://www.kinston.com/news/20190513/minimally-invasive-procedure-can-reduce-stroke-risk

Stealthy catheter developer Route 92 Medical, which is developing a catheter to treat stroke, last week said it raised nearly $13 million in an equity round.

Founded in 2015, San Mateo, Calif.-based Route 92 won 510(k) clearance from the FDA a year ago for a percutaneous catheter. The company holds U.S. patents for treating acute ischemic stroke, a rapid aspiration thrombectomy system and intra-cerebral implant delivery.

According to regulatory filings, Route 92 first drummed up $5.9 million in May 2016. Just less than a year later the company doubled that raise, adding another $4.7 million in August 2018. Including the most-recent May 25 filing, Route 92 Medical has raised $29.5 million in equity rounds.

Read More: https://www.massdevice.com/stealthy-route-92-medical-raises-13m/

SUNNYVALE, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended March 31, 2019.

Recent Highlights

• Recorded revenues of $12.8 million for the first quarter of 2019, representing a 124% increase over the first quarter of 2018
• Completed initial public offering of six million shares, raising approximately $108.8 million in net proceeds, after deducting underwriting fees and other expenses
• Completed enrollment in the ROADSTER 2 study
• Clinical data from the TCAR Surveillance Project to be presented at the Society for Vascular Surgery’s Vascular Annual Meeting in June​​

​“At Silk Road Medical, we are motivated by relentless dedication to successful patient outcomes and by our focus on two key priorities of expanding the clinical evidence and U.S. commercial execution. We are pleased to report first quarter results which reflect these priorities,” said Erica Rogers, Chief Executive Officer. “Commercial momentum is achieved by driving physician adoption of TCAR procedures which recently surpassed 10,000 globally. We are simultaneously progressing forward with clinical evidence and are pleased to announce that we have completed enrollment in our ROADSTER 2 study.”

Read More: https://www.globenewswire.com/news-release/2019/05/08/1819696/0/en/Silk-Road-Medical-Reports-First-Quarter-2019-Financial-Results.html